The initiation of a second Phase 3 clinical trial for bomedemstat demonstrates company’s commitment to advancing research in myeloproliferative neoplasms (MPNs)
CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
To co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where Merck retains exclusive rights
Acquisition strengthens and diversifies Merck’s pipeline with the addition of Restoret
An investigational CYP11A1 Inhibitor, for the treatment of metastatic castration-resistant prostate cancer
The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer
Acceptance based on results demonstrated a statistically significant improvement in overall survival versus chemotherapy alone in these patients
Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration
Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
Subscribe To Our Newsletter & Stay Updated
